Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Nextcure Inc (NXTC)

Nextcure Inc (NXTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor Business Wire - Mon Nov 28, 2022

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief...

ACHN : 0.7912 (-21.66%)
ARVN : 23.90 (-3.82%)
NXTC : 1.5700 (+4.67%)
BHVN : 33.79 (-1.11%)
INZY : 4.49 (+1.58%)
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM Globe Newswire - Mon Jun 27, 2022

BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 1.5700 (+4.67%)
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM Globe Newswire - Mon Jun 27, 2022

BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 1.5700 (+4.67%)
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Globe Newswire - Wed Jun 22, 2022

BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 1.5700 (+4.67%)
NextCure to Present at the JMP Securities Life Sciences Conference Globe Newswire - Wed Jun 8, 2022

BELTSVILLE, Md., June 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 1.5700 (+4.67%)
Chau Khuong Joins Catalio Capital Management as General Partner Business Wire - Wed May 25, 2022

Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced that Chau Khuong, who was most recently a Partner at OrbiMed Advisors, has joined...

FUSN : 21.55 (+0.14%)
GKOS : 119.29 (+0.26%)
NTLA : 22.95 (+3.61%)
ICPT : 19.00 (+0.21%)
INSP : 133.94 (-0.23%)
NXTC : 1.5700 (+4.67%)
PIRS : 8.68 (+1.28%)
Oversold Conditions For NextCure (NXTC) Dividend Channel - Fri Apr 29, 2022

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

NXTC : 1.5700 (+4.67%)
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results Globe Newswire - Thu Mar 3, 2022

Multiple data readouts expected in 2022, including updates for all three clinical programs Ends 2021 with cash position of $219.6 million that is...

NXTC : 1.5700 (+4.67%)
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference Globe Newswire - Tue Feb 8, 2022

BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 1.5700 (+4.67%)
NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting Globe Newswire - Mon Dec 13, 2021

BELTSVILLE, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 1.5700 (+4.67%)

Barchart Exclusives

3 Mid-Cap Energy Dividend Stocks to Scoop Up Now Barchart - Wed Jul 3, 6:30PM CDT
Amid predictions of higher oil prices, here are three dividend-paying energy stocks that are worth adding to your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot